Recently, Beijing JILUNTAI Pharmaceutical Co., Ltd. ("JILUNTAI"), a nuclear medicine innovation company invested and incubated by Baheal Pharma Group, achieved a significant R&D milestone. Its independently developed Class 1 innovative therapeutic radiopharmaceutical, ¹⁷⁷Lu-JLT003 injection (generic name: ¹⁷⁷Lu-AB-3PRGD2), has officially received an Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The drug is intended for the treatment of integrin αvβ3-positive malignant tumors.

On June 25, 2026, the first ZAP-X Gyroscopic Radiosurgery Robot ("ZAP-X") unit produced at High-end Manufacturing Industrialization Base (hereinafter "the Base") was officially loaded and dispatched from The Airport Economic Zone of Beijing Daxing International Airport (Langfang Area). This marks the first time this globally leading precision brain radiotherapy device has achieved "Made in China, and delivered globally," and represents a significant milestone for Baheal Medical (301015.SZ) in deepening its footprint in the precision radiosurgery sector and completing its full-industry-chain layout. Leveraging China's supply chain strengths, the company will steadily expand its global supply capabilities for high-end radiotherapy equipment, further sharpening its competitive edge in the radiosurgery market worldwide.

On March 9, 2026, SicaGene announced that its proprietary Class I innovative drug candidate, SG12 Injection (“SG12”) for the treatment of chronic hepatitis B (CHB), has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA).

On December 25th, 2025, RabPharma Biopharma Co., Ltd. (“RabPharma”) announced that the Investigational New Drug (IND) application for a new indication of its core pipeline candidate, RAB001 for injection, has been approved by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The newly approved indication expands the clinical development of RAB001 into knee osteoarthritis, marking the second IND approval obtained for this innovative bone regenerative therapy. The IND approval (Acceptance No. CXHL2501164) represents an important milestone in broadening the clinical application of RAB001 from osteonecrosis to osteoarthritis, one of the world’s most prevalent degenerative musculoskeletal diseases.

Baheal Pharma Group has been named among the "Top 30 Strategic Investors / CVCs in China" in Zero2IPO Research Center's 2025 China Venture Capital & Private Equity Annual Ranking, reflecting the Group’s sustained commitment and proven track record in healthcare innovation investment and incubation.